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Introduction. The high cost and concern of adverse events, particularly infections, limit the use of biologic 
disease-modifying anti-rheumatic (bDMARD) therapies. We undertook this retrospective study to document 
their use for immune-mediated diseases (IMDs) and explore the efficacy, safety, adherence and screening 
practices prior to initiating bDMARDs in a tertiary referral hospital.  
Methods. A folder review of all adult and paediatric patients treated for IMDs with bDMARDs at Groote Schuur 
and Red Cross Hospitals between January 2013 and December 2019. Clinico-demographic particulars, details of 
bDMARD therapy, and adverse events were collated. Changes in disease activity were measured by disease-
specific tools at 6, 12, 24-months and at the last available visit, and patient adherence to bDMARDs was explored 
by folder and pharmacy record review.  
Results.  We studied 151 folders, with 182 bDMARDs uses (29 patients used more than 1 bDMARD). Patients 
were from rheumatology (n= 38: 13 rheumatoid arthritis; 10 spondyloarthritis, 5 Systemic Lupus Erythematosus 
(SLE) , 5 inflammatory myositis and 5 other conditions);  gastroenterology (n=31; 26 Crohn`s and 5 Ulcerative 
Colitis), dermatology (n=9; psoriasis), neurology (n=4, ophthalmology (n= 25; 6 scleritis, 18 uveitis, 1 optic 
neuritis), and paediatrics (n= 45, 26 juvenile idiopathic arthritis , 12 SLE, 7 other conditions). The bDMARDs used 
were TNF inhibitors (112), rituximab (55), tocilizumab (10), anakinra (3), abatacept (1), and tofacitinib (1). 
The vast majority of patients had an excellent response and were in low disease activity or remission at their last 
available visit.  Adverse events included severe infection (4), tuberculosis (TB) (2), mild infection (4), severe 
allergic reaction (3), mild skin reaction (14), elevated liver enzymes (2), and worsening interstitial lung disease 
ILD (1).  bDMARD Therapy was discontinued in 18 patients, most commonly due to adverse reaction (9), lack of 
response (3), poor adherence (2), or remission (1). bDMARD Therapy was changed to alternative therapy in 29 
patients, most commonly because of poor response (14), or adverse effects (9) or poor adherence (3). Poor 
adherence or patients lost to follow-up was noted in 18/182 (9.9%). Complete latent TB infection screening with 
chest x-ray and TB skin test was performed in only 55 (36.4 %) but INH prophylaxis was given to 51/88 (57.9%) 
of patients prescribed TNFi therapy. Hepatitis B screening performed in 93 (61.6 %) patients, but most patients 
(72.2 %) were not tested for Hepatitis B core ab. Hepatitis C screening was performed in 81 (53.6 %) patients. 
Only 88 (58.3%) patients had a recent HIV test. The majority (17.2%) received the influenza vaccine, but only 24 
(15.8 %) received pneumococcal vaccination.  
Discussion and Conclusion. bDMARD therapy was an effective treatment, and the most common adverse effect 
was infection (7.2%), with 2 TB infections. Vaccination and screening for TB, viral hepatitis and HIV was 
suboptimal. Of concern, poor adherence to bDMARDs was frequently encountered.     
 
Key points 
bDMARDs are effective treatment 
The most common adverse effect was the infection 
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Chapter 1: The literature review 
 
Background:     
Numerous biologic disease-modifying anti-rheumatic drugs (bDMARDs) have been developed 
over the last two decades, targeting inflammatory cytokines, cytokine receptors or cells 
within the synovium and immune system. These therapies have dramatically improved 
outcomes in patients with immune-mediated diseases (IMDs) and are indicated in patients 
with a poor response to conventional therapy. Recommendations for their use have been 
published by international and local South African associations including the European League 
Against Rheumatism (EULAR) and by the South African Rheumatism and Arthritis Association 
(SARAA)(1,2). 
Nine bDMARDs are currently registered and available in SA with good efficacy and safety 
profile. These include tumour necrosis factor inhibitors (TNFi) which are  Infliximab (IFX),  
Etanercept (ETN),  Adalimumab (ADA),  Golimumab (GOL); and the non-TNFi, which are 
Abatacept (ABT), Rituximab (RTX), Tocilizumab (TCZ), Ustekinumab (UTK) and Secukinumab 
(SCK)(3). 
The management of any IMDs requires a multiple disciplinary team, shared decision between 
patients and physician, holistic consideration of the disease and its therapy’s medical and 
social costs. Below we briefly describe each IMD, the tools used for the measurement of 
disease activity, and the indication and specific bDMARDs that are useful. Tables 1 -3  show 
summaries of bDMARDs and each disease-specific measurement. 
 
Rheumatoid Arthritis: 
Rheumatoid Arthritis (RA) is a polyarticular inflammatory disease with the potential to cause 
significant disability from joint inflammation and progressive joint destruction(4). Disease 
activity is measured by the Clinical Disease Activity Index (CDAI), comprising the number of 
swollen and tender joints, and patient self and physician global assessments(5). The Health 
Assessment Questionnaire Disability Index (HAQ-DI) measures functional disability (6).   
In refractory disease, bDMARDs control inflammation, prevent joint damage and improve 
functional disability(2). Against this background, SARAA recommends the use of bDMARD for 
RA in patients who have failed a 6 month trial of at least three conventional synthetic disease-
modifying anti-rheumatic drugs (csDMARDs), including Methotrexate (MTX), Sulphasalazine 
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(SSZ) and Leflunomide(2). EULAR also considers bDMARD in treatment for RA if treatment to 
target is not achieved with first csDMARDs in the presence of poor prognostic factors 
(persistent moderate or high disease activity despite csDMARDs, high acute phase reactant, 
high swollen joint count, presence of early erosions, presence of rheumatoid factors (RF) and 
anti-citrullinated peptide antibody (ACPA) especially in high level, and failure of two or more 
csDMARDs) (1). 
 
Psoriatic and Psoriatic Arthritis: 
Psoriasis (PsO) is a chronic skin disorder that affects 2.2% of the population in the united 
states, characterized by thick, inflamed red patches often covered with silvery scales on the 
skin(7). Topical agents are the first line but systemic therapy with csDMARDs must be 
considered for severe disease, and patients failing to respond to csDMARDs require bDMARDs 
(8,9). EULAR  recommends bDMARDs for the management of moderate to severe PsO not 
responding to other systemic therapies (10). In PsO, disease activity is assessed by body 
surface area (BSA) and Psoriasis Area and Severity Index (PASI). A BSA >10% signifies 
moderate to severe disease activity,  and a PASI score of 12 is a minimum for entry into many 
clinical trials (11).  
 
Psoriasis can be associated with arthritis termed psoriatic arthritis (PsA), which can lead to 
joint damage, functional impairment and increased mortality(12). Disease activity scores 
include the Psoriatic Arthritis Disease Activity Score (PASDAS), and Composite Psoriatic 
activity Disease Index (CPADI), but the CDAI used in RA is also frequently used(13).  The 
treatment of active PsA includes early csDMARDs. If the patient is unresponsive to at least 
one csDMARD, bDMARDs should be considered. These include TNFi, interleukin-17 (IL-17) or 
interleukin-12/23 ( IL-12/23) inhibitors(14). Studies have shown that treatment of psoriatic 
arthritis with TNFi (ETN, ADA, or IFX) is highly effective with significant improvement in 
disease activity, functional status, and skin scores(15).  
 
Spondyloarthritis:  
Seronegative spondyloarthropathies (SpA) are a group of inflammatory rheumatic diseases 
with axial and peripheral arthritis, enthesitis, extra-articular manifestations and HLA- B27 
association(16). The untreated disease has a negative impact on patient life, fatigue, 
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depression, sleep problems, and sexual function (17). The Ankylosing Spondylitis Disease 
Activity Score (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
are a reliable measurement of disease activity, response to treatment and can be used in daily 
clinical practice(18). The first-line pharmacological treatment for axial SpA is non-steroidal 
anti-inflammatory drugs (NSAIDs). For persistent high disease activity despite two different 
NSAIDs, bDMARDs should be considered -  including TNFi or IL- 17 inhibitors(19). SARAA 
recommends the use of TNFi in patients with persistently elevated BASDAI (≥4) despite 2 
NSAIDs(3).In clinical trials of patients with active SpA, treatment with TNFI has shown 
improvement in function and disease activity, together with reduced radiographic 
progression(20–22).  
 
Systemic lupus erythematosus:  
The systemic lupus erythematosus (SLE) is a chronic IMD that can affect any organ and system 
of the body with a wide range of complications and significant morbidity and mortality. The 
most commonly used tools to assess disease activity in lupus are the SLE Disease Activity Index 
(SLEDAI and the British Isles Lupus Assessment Group (BILAG)(23).  
Antimalarial treatment, such as chloroquine, is recommended for all patients with SLE unless 
contraindicated. Early and prompt initiation of immunosuppressive therapy expedites 
tapering of glucocorticoids. In refractory organ-threatening disease, and particularly in 
haematological, neurological and renal manifestations, RTX should be considered(24). 
In a systematic review of 188 patients treated with RTX, 171 of the 188 patients showed 
significant improvement in one or more of the systemic SLE manifestations(25). Rituximab is 
useful in the treatment of haematological disease, refractory nephritis, and neuropsychiatric 
systemic lupus erythematosus (NPSLE)(26).  
 
Juvenile Idiopathic Arthritis: 
Juvenile Idiopathic Arthritis (JIA) is a chronic arthritis of childhood and is the most common 
cause of musculoskeletal disability in children(27). This disease is divided into several 
subgroups including systemic JIA, seronegative polyarticular JIA, seropositive polyarticular 
JIA, oligoarticular JIA, enthesitis-related arthritis and juvenile psoriatic arthritis(28,29). 
Untreated disease can lead to persistent inflammation which results in muscle atrophy, 
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flexion contraction and leg length inequality(30). There is no single measure that can reliably 
capture overall disease activity in all JIA phenotypes. Composite diseases activity scores 
including Juvenile Arthritis Disease Activity Score (JADAS) with multiple versions, the Juvenile 
Arthritis Parent Assessment Index (JAPAI), the Juvenile Arthritis Child Assessment Index 
(JACAI), the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) and the Juvenile 
Spondyloarthritis Disease Activity Index (JSpADA) are some of composite disease activity 
indices used for children and adolescents in JIA(31). For JIA with inadequate response to 
csDMARDs, bDMARDs including TNFi, anakinra, RTX, ABT and TCZ are indicated(32,33). 
bDMARDs in patients with JIA may lead to remission, improved quality of life, with normal 
growth and good long term functional outcome(27,32–34).  
 
 Inflammatory Bowel Disease: 
Inflammatory Bowel Disease (IBD) encompasses Crohn’s Disease (CD), characterized by 
transmural inflammation affecting any part of the gastrointestinal tract, and Ulcerative Colitis 
(UC) which causes diffuse mucosal inflammation confined to the colon(35). Serious 
complication includes a fistula, abdominal abscess, toxic colitis, pouchitis and primary 
sclerosing cholangitis(36). Disease activity in IBD is measured using clinical parameters, like a 
daily bowel movement, presence of bloody diarrhoea and laboratory measures like ESR, CRP 
and Hb(37). In Crohn’s disease, the CDAI and Van Hees index(VHI) is used, together with 
histological and endoscopic indices for mucosal monitoring(38). For ulcerative colitis, it is 
essential to measure the extent of inflammation by endoscopy or x-ray examination of the 
bowel(38). Monoclonal TNFi such as IFX has been approved for the treatment of inflammatory 
and fistulating CD. Others TNFi have emerged for IBD, including certolizumab, GOL and ADA. 
(39). A Cochrane meta-analysis, and open-label extension follow-up and cohort studies 
confirm that ADA, IFX, and certolizumab have successfully induced and maintained remission 
in Crohn's disease(39,40). In addition, the combination of IFX and azathioprine promotes 
mucosal healing and induces steroid-free remission better than azathioprine or IFX alone(40). 
In the last two decades in SA, bDMARDs have shown impressive results(41). 
 
Immune-mediated myositis:  
Idiopathic inflammatory myopathy (IMM)s are characterized by an inflammatory infiltrate in 
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the muscle and can affect other organs, particularly the lungs(42). IMMs are classified into 
dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM)(43,44). 
Treatment of IIMs include glucocorticoids combined with immunosuppressants(45). RTX and 
ABT are promising treatments for IIMs and for treating immune-mediated ILD(46–50). The 
core set measures (CSM) and conjoint-analysis survey are used as response criteria in 
IMM(47).  
 
Juvenile dermatomyositis  
Juvenile dermatomyositis (JDM) is a chronic autoimmune disease characterised by 
symmetrical proximal muscle weakness and skin involvement(51). The standard treatment 
includes the combination of a high dose of intravenous or oral Glucocorticoids, and MTX(51). 
The Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) initiative 
recommendation for the treatment of refractory JDM includes adding Intra Venous Immuno-
Globulins (IVIG) or changing MTX to Cyclosporine A, Mycophenolate Mofetil (MMF), or 
bDMARDs which includes RTX, IFX or ADA(52). Regular reviews include assessment of skin 
disease, muscle strength, major organs involvement, and patient/parent report outcome 
measures(52). Measures of disease activity include patient/parent global health score, 
physician global, patient pain score and childhood myositis assessment score (CMAS), which 
is the most commonly used assessment tool(53).  
 
Uveitis and Scleritis: 
Uveitis is inflammation of the uveal tract including the iris, ciliary body and choroid, and 
maybe a part of systemic diseases such as SpA, IBD, JIA, Bechet’s and Sarcoidosis. Uveitis is 
the most common ophthalmological finding in rheumatology and clinical immunology and can 
lead to amblyopia, significant morbidity, and blindness(54). Off-label use of bDMARDs, 
particularly monoclonal TNFi are very effective in refractory uveitis and retinal vasculitis and 
improve quality of life(55–57). The  Standardization of Uveitis Nomenclature (SUN) criteria is 
used to measure disease activity in uveitis however, it only takes into account inflammation 
in the anterior chamber and vitreous haze. The Uveitis Disease Activity Index (UVEDAI) and 
visual acuity (VA) are used to assess disease activity(58,59).  
 
Scleritis is inflammation of the sclera can be classified to anterior and posterior or necrotizing 
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and non-necrotizing(60). bDMARDs are indicated for scleritis that poorly responds to 
corticosteroids and/or to immunosuppressive treatment. Monoclonal TNFi including IFX and 
ADA are superior to ETN for the treatment of refractory scleritis.  In scleritis associated with 
vasculitis, RTX is the best option(61). Ophthalmological clinical evaluation is used to assess 
scleritis and the response to bDMARDs(62).  
 
ANCA-associated vasculitis and Bechet’s disease: 
Vasculitis is the inflammation of the vessels wall with or without necrosis. The Birmingham 
Vasculitis Activity Score (BVAS), The Birmingham Vasculitis Activity Index (BVAI) for 
Granulomatosis with polyangiitis (GPA) (BVAI/GPA), a Physician Global Assessment (PGA), the 
Disease Extent Index,(DEI), and the Five-Factor Score(FFS) are globally accepted as vasculitis 
disease activity measurement tools(63). RTX or cyclophosphamide regimens lead to sustained 
remission in ANCA- associated vasculitis(64,65).  
 
Bechet’s disease (BD) is a multisystem disease characterized by oral and genital ulcers, eye 
involvement (uveitis, retinal vasculitis), neurological involvement (stroke, 
meningoencephalitis), articular involvement, skin involvement, GIT involvement and vascular 
involvement(arterial and venous thrombosis, aneurysm)(66). Both TNFi (IFX and ADA) are 
effective treatments(67). The Behçet's Syndrome Activity Scale (BSAS) and the Behçet's 
Disease Current Activity Form (BDCAF) were useful measurements to assess disease activity.  
Of BD(68).  
 
IgG4 sclerosing-related disease: 
IgG4 sclerosing-related disease (IgG4-RD) is multi-organ IMD links that mimic inflammatory 
conditions, infection and malignancy. The pathological features are lymphoplasmacytic 
infiltration, fibrosis and obliterative phlebitis. Untreated disease can lead to organ damage 
with extensive fibrosis and death(69). Serial treatment with RTX leads to better control of the 
disease activity and a decrease in serum IgG4 concentration(70). The IgG4-RD Responder 
Index (RI)  is a reliable and valid disease activity assessment that can be used to assess 
response to treatment(71). 
 
 Safety of biologics: 
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Although bDMARDs are highly effective in treating IMD’s, important safety concern has 
emerged. These include administration reactions, infection, malignancy, demyelinating 
disease, congestive heart failure and hyperlipidemia(72). 
 
Infections 
Biologic therapy increases the risk of both mild and serious infections(2,73). In sub-Saharan 
Africa, there is a heavy burden of infectious diseases, including tuberculosis (TB), HIV, 




All RA patients in SA are at increase the risk of TB, and this risk is increased with age (≥60 
years), previous TB infection, low socioeconomic status and high-risk occupation or dwelling, 
for example, health worker, homeless and prisoner-staff(2). Most importantly, the 
background risk of TB influences the risk of reactivation of latent TB infection (LTBI) or 
reinfection with TB(2). bDMARDs have an increased the risk of TB, however, the risk of TB 
between bDMARDs varies significantly with the highest risk with TNFi particularly ADA and 
IFX, and the lower risk of TB associated with newer TNFi and other bDMARDs(74).  In countries 
with a high risk of TB, non-TNFi should be considered the first-line bDMARD for RA, because 
of the risk of TB associated with TNFI(75). Because of TNF-α ‘s role in maintaining granuloma 
integrity,  TNF inhibition is associated with reactivation of latent TB, in experimental models 
and in human patients(76). The TB risk is 3-4 times higher in monoclonal TNFi than soluble 
TNFi (ETN)(77).  Similarly, interleukin-1 (IL-1) is essential for host resistance to mycobacterium 
TB, and IL-1 inhibitors are associated with an increased risk of TB infection and 
reactivation(76). Interleukin-6 (IL-6) is associated with differentiation of IL-17 and interleukin-
22 (IL-22) which possesses anti-mycobacterial properties, and IL-6 deficiency associated with 
TB death in mice(76). The TB risk of a patient treated with RTX or ABT was negligible, and the 
TB screen has been suggested to be unnecessary(76). However, a recent retrospective review 
of the SA bDMARD registry show occurrences of TB in all bDMARD users(78). From the 
available evidence and SCK appear safe in a patient with latent TB(76).  
 
Screening for active TB with a chest X-ray (CXR) together with screening for LTBI with either a 
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tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA) is mandatory before 
commencing bDMARD. Both tests only measure the magnitude of effectors' memory T cells 
response to previous or recent exposure, and neither of these tests distinguishes LTBI from 
active TB. Patients with a positive test are more likely to develop TB within the next two 
years(2,79). Screening LTBI and offering isoniazid (INH) prophylaxis for positive cases has 
resulted in a marked reduction in TB risk and is now part of international and local 
recommendations before commencing biologic therapy(2,80). Recommendations are that 
patients complete at least 4 weeks of INH therapy prior to starting a TNFi. However, studies 
have shown that adherence to these recommendations is poor(81,82). Many state-sector 
rheumatology services in SA including GSH, have taken the decision to offer continuous INH 
prophylaxis for an extended period for the duration of TNFi therapy to all patients’ prescribed 
TNFi therapy, regardless of LTB screening results. 
 
Viral Hepatitis 
The bDMARDs infer a risk of reactivation of Hepatitis B and C viruses, and RTX, in particular, 
has a greater risk of hepatitis B virus reactivation(83). Screening with Hepatitis B surface 
antigen (HBsAg), anti-hepatitis B surface (anti-HBs), anti-hepatitis B core total (HBcab), 
Hepatitis C virus antibodies (HCV ab) should be done in all patients before commencing 
biologic therapies(84,85).  
 
Other infections 
All bDMARDs infer an increase of serious and mild infections. Patients and health care workers 
need to be aware of this risk and to assess and treat unwell patients rapidly with a high index 
of suspicion for infection. In particular, tofacitinib increased the risk of herpes zoster 
infection(86). The most common adverse effect of anakinra was pneumonia and 
gastroenteritis(87). HIV-infected individuals have not been included in randomized control 
trials of bDMARDs because of increased risk of infection so the use of bDMARD therapy in HIV 
positive patients is limited to case series and case reports and needs further study(88).  
 
Vaccination: 
Before commencing bDMARDs, patients need immunization for influenza, pneumococcal, 
human papillomavirus and hepatitis B virus. Live vaccines including herpes zoster and yellow 
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fever are not recommended(2,89). 
Other side effects 
An uncommon but serious adverse effect of TNFi includes uveitis, drug-induced SLE and 
demyelination(Table 4)(90). The most common side effects of TCZ include serious infection, 
elevated liver enzymes, and neutropenia(91). The most common adverse effect of RTX is 
infusion reactions, neutropenia, with concerns of progressive multifocal 
leukoencephalopathy, and agammaglobulinemia in long-term use(79,92). Treatment with 
ABT is associated with lower risks of infection, autoimmune events, and infusion 
reactions(93). Adverse effects of tofacitinib include gastrointestinal perforation, increased 
risk of malignancy and major cardiovascular events(86). The most frequent adverse effects of 




Studies have shown that TNFi is safe throughout pregnancy and are not associated with an 
increase in maternal or foetal adverse events except for the risk of neonatal TB following 
Bacillus Calmette Guerin (BCG) vaccination, which should be deferred(94). Tofacitinib should 
be discontinued at least 6 weeks before planned pregnancy and during breastfeeding(95). 
Anakinra can be used in pregnancy in the absence of alternative treatments(96). There is 
insufficient data on the safety of RTX, belimumab, UTK SCK, and TCZ and these should be 
avoided during pregnancy and breastfeeding(96). 
 
Adherence and support: 
Adherence to bDMARDs is less than expected. In a recent study of RA patients treated with 
bDMARDs in five different European countries, 56.3% of patients missed a dose over 6 
months. The reasons for noncompliance were feeling better and didn’t need it, thinking the 
therapy was not helping, sickness, surgery or infection(97). Similarly, adherence in PSO is low 
with a high discontinuation rate(98).  
 
Adverse effects, particularly infection and TB, together with the high cost of these therapies, 
hampers their widespread use and makes evaluation of efficacy and safety practices 
associated with their use vital(3). We undertook this retrospective review of all patients 
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treated with bDMARDs for IMD in the last 7 years at Groote Schuur and Red Cross Hospitals 
to measure the efficacy, safety, and adherence of patients to biologic treatment. This will 
promote a deeper understanding of the use of these therapies in sub-Saharan, Africa and will 
allow better planning of future health care services.  
 
Table-1 Biologic DMARDs available in EULAR - mechanism of action of and indications 
Biologic Drug Mechanism of action Registered indications Off-label indications 
Infliximab Monoclonal antibody against TNF ά 
(Murine and human antibody) 
AS, CD, JIA, PsA, RA, UC 
Hidradenitis suppurativa  
Plaque psoriasis 










Adalimumab Fully Human Monoclonal antibody 
against TNF-ά 
Golimumab Fully human Monoclonal antibody 
against TNF ά 
Etanercept Fusion protein fused with FC portion 
of human IgG1 and block against TNF-
ά  
Abatacept Soluble fully human Fusion protein 
inhibitor T-cell co-stimulation 
RA, JIA, PsA 
 
 
Rituximab Chimeric Mouse/human monoclonal 
antibody against CD 20+ B cells 






Tocilizumab Humanized monoclonal antibody 
targeting IL 6 receptor  
RA, sJIA, NMO, GCA Crohn’s disease, SLE. 
PMR 
Ustekinumab IL-12/23 monoclonal antibody PSO, PsA, CD  UC 
Secukinumab IL-17 inhibitor  PSO, PsA, AS  
Tofacitinib Janus kinase (JAK) inhibitor RA, UC  
    
AS: Ankylosing Spondyloarthritis; CD: Crohn’s Disease: CLL: Chronic Lymphocytic Leukemia; GCA: 
Giant Cell Arteritis; IBD: inflammatory bowel disease; JIA: Juvenile Idiopathic Arthritis; MPA: 
Microscopic Polyangiitis; NHL: Non-Hodgkin Lymphoma; NMO: Neuromyelitis Optica; PSO: psoriasis; 
PsA: Psoriatic Arthritis; PMR: Polymyalgia Rheumatica; RA: rheumatoid arthritis; sJIA: Systemic 
Juvenile Idiopathic Arthritis; SLE: Systemic Lupus Erythematosus; UC: Ulcerative Colitis; GPA: 
Granulomatous with polyangiitis.  
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Table 2 Dose and administrative route of Biologic DMARDs currently available in EULAR 
Biologics Half-life(days) Route  Dose (adult patients) Dose (Pediatric patients) frequency 
Infliximab 8-10 IV 3mg/kg 3mg/kg 8 weeks 
Adalimumab 10-20 S/C 40mg. 20 mg in children < 30kg 2 weeks 
Etanercept 4 S/C 50mg 
 
.8mg/kg weekly 
Golimumab  S/C 50mg   Monthly 




2 doses 2 weeks 
apart every 
6months or at 
disease flare 
Tocilizumab 13 IV 8mg/kg 8mg/kg 2 weeks 
Abatacept 8-25 IV 500mg, 750mg, or 1000mg  -If < 75 kg: 10 mg/kg IV 
-If 75 kg to 100 kg: 750 
mg IV 
-If > 100 kg: 1000 mg IV 
-Maximum dose: 1000 mg 
4 weeks 
Ustekinumab 20-39 S/C 45mg if weight ≤  100 kg 
90mg if weight ≥ 100 kg 
 12 weeks 
Secukinumab 17-41 S/C 150mg   4 weeks 
 
Abbreviations: 
IV: Intravenous; S/C: Subcutaneous; M2: meter squire. 
 




Table 3: Disease-specific outcome measures 
 Disease  Disease activity measurement 
RA  CDAI, C- Reactive Protein (CRP) 
AS  BASDAI, BASFAI, CRP 
Psoriasis  PASI, BSA%, Clinical features 
(C/F), EIS 
PsA  CPADI, CDAI 
IBD  C/F, colonoscopy, CDAI 
IgG4-RD  C/F, IgG4-RD(RI) 








Pulmonary vasculitis, shrinking 
lung syndrome 
Lung function tests (including 
DLCO) 
nephritis Remission criteria 
Arthritis CDAI 
thrombocytopenia Platelet count 
Neurolupus C/F 
AOSD  CDAI, CRP 
IMMs  CK, CSM, C/F, CMAS for JDM 
Vasculitis-GPA  C/F, BVAI/GPA  
Behçet’s disease   BSAS, BDCAF 
PAN   C/F, BVAS 
MPA-ILD  Lung function tests C/F 
MPA  UPCR, Cr 
Uveitis  VA, C/F, IOP 
Myasthenia Gravis  MG composite score, C/F 
Multiple sclerosis  EDSS, C/F 
NMO  C/F 
CRMO  C/F 
Sweet syndrome  C/F 
Autoinflammatory syndrome  C/F 
 
Abbreviations: BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFAI: Bath Ankylosing 
18 
 
Spondylitis Function Activity Index; BDCAF: Behçet's Disease Current Activity Form; BSAS: Behçet's 
Syndrome Activity Scale; BVAI/GPA: Birmingham Vasculitis Activity Index for Granulomatosis with 
polyangiitis; BVAS: Birmingham Vasculitis Activity Score; CDAI: Clinical Disease Activity Index; CRP: C 
Reactive Protein; C/F: Clinical Features;  CK: Creatinine Kinase; CMAS: Childhood Myositis 
Assessment Score; CSM: Core Set Measures; cJADAS-10: clinical  Juvenile Arthritis Disease Activity 
Score-10 joints; IgG4-RD(RI): IgG4-RD Responder Index; JACAI: Juvenile Arthritis Child Assessment 
Index; JSpADA: Juvenile Spondyloarthritis Disease Activity Index; PASI: Psoriatic Area Severity Index; 
BSA%: Body Surface Area%; EIS: Erythema, Induration, Scaling; VA: Visual Acuity; IOP: Intra Ocular 
Pressure; NMO: Neuro Myelitis Optica; CRMO: Chronic Recurrent Multifocal Osteomyelitis. 
 
Table 4: Adverse effects of Biologic DMARDS and preventative measures 
problem bDMARD risk Other risks prevention 
 
Tuberculosis  
monoclonal TNFi >. soluble 
TNFi > non-TNFi. (TCZ (very low 
risk), tofacitinib)  
…. Screening for LTB, INH prophylaxis 
Hepatitis B Virus RTX 
TNFi 
Other biologic drugs 
 
GC, Anthracycline 
derivative’s (Doxorubicin)  
 
Screening for HBV S Ag, HBV Core Ab before 
immunosuppression. 
Prophylaxis of patient with HBc Ab +ve. 
 
Hepatitis C Virus There is no risk of reactivation 
with immunosuppressive 
drugs.  
 HCV Ab, if positive HCV RNA should be 
checked. 
Contraindication in liver dysfunction 
classified as Child–Pugh class B and higher 
Urinary Tract Infections  ABT   
URTI and LRTI 
(pneumococcal, 
Influenza, PCP)  
TNFi, ABT, TCZ, UTK, SCK, 
tofacitinib, anakinra 
HIV, GCs. Vaccination, prophylaxis treatment for PCP   
 
Herpesvirus (EBV, CMV, 
HSV, VVZ)  
VZV (TNFi)  
HZV Tofacitinib 
EBV (Thiopurine, Aza) 
CMV (steroid severe 
refractory IBD) 
immunosuppression 
Check VZ Ab before commencing 
immunosuppression. In the presence of 
negative tests, vaccination should be offered 
a least 4 weeks before immunosuppression 
Neutropenia TCZ csDMARDs Full Blood Count (FBC) 
Demyelination TNFi 
 
Checkpoint inhibitor with most cases having a partial or complete response 





 Watch for neurological symptoms if present 
considers MRI and virus antibody.  
transaminitis TCZ 
ABT 
 Follow up by liver function test  
Dyslipidemia TCZ  Lipid profile  
GIT perforation  TCZ   
Infusion reaction  TNFi, RTX, ABT, TCZ, UTK, SCK  Sow infusion, and watch for rash and itching, 
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Introduction. The high cost and concern of adverse events, particularly infections, limit the 
use of biologic disease-modifying anti-Rheumatic drugs (bDMARD) in South Africa. We 
undertook this retrospective study to document their use for immune-mediated diseases 
(IMDs) and explore the efficacy, safety, adherence and screening practices prior to initiating 
to bDMARDs in a tertiary referral hospital.  
Methods. A folder review of all adult and paediatric patients treated for IMDs with 
bDMARDs at Groote Schuur and Red Cross Hospitals between 01/2013 and 12/2019. Clinico-
demographic particulars, details of bDMARD therapy, and adverse events were collated. 
Changes in disease activity were measured by disease-specific tools at 6, 12, 24-months and 
at the last available visit, and patient adherence to bDMARDs was explored by folder and 
pharmacy record review.  
Results.  We studied 151 folders, with 182 bDMARDs uses (29 patients used more than 1 
bDMARD). Patients were from rheumatology (38) gastroenterology (31); dermatology (9), 
neurology (4), ophthalmology (25;), and paediatrics (45). The bDMARDs used were tumour 
necrosis factor inhibitors (TNFi) (112), rituximab (55), tocilizumab (10), anakinra (3), 
abatacept (1), and tofacitinib (1). 
The vast majority of patients had an excellent response and were in low disease activity or 
remission at their last available visit.  Adverse events included severe infection (4), 
tuberculosis (TB) (2), mild infection (4), severe allergic reaction (3), mild skin reaction (14), 
elevated liver enzymes (2), and worsening interstitial lung disease (ILD) (1).  bDMARD 
therapy was discontinued in 18 patients, most commonly due to adverse reaction (9), lack of 
response (3), poor adherence (2), or remission (1). bDMARD Therapy was changed to 
alternative therapy in 29 patients, most commonly because of poor response (14), or 
adverse effects (9) or poor adherence (3). Poor adherence or patients lost to follow-up was 
noted in 18/182 (9.9%). Complete latent TB infection screening with chest x-ray and TB skin 
test was performed in only 55 (36.4 %) but isoniazid prophylaxis was given to 51/88 (57.9%) 
of patients prescribed TNFi therapy. Hepatitis B virus (HBV) screening performed in 93 (61.6 
%) patients, but most patients (72.2 %) were not tested for HBV core antibody. Hepatitis C 
virus screening was performed in 81 (53.6 %) patients. Only 88 (58.3%) patients had a recent 
human immune virus (HIV) test. The majority (17.2%) received the influenza vaccine, but 
only 24 (15.8 %) received pneumococcal vaccination.  
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Discussion and Conclusion. bDMARD therapy was an effective treatment, and the most 
common adverse effect was infection (7.2%), with 2 TB infections. Vaccination and 
screening for TB, viral hepatitis and HIV was suboptimal. Of concern, poor adherence to 
bDMARDs was frequently encountered.     
 
Key points 
The most common adverse effects of bDMARDs are mild infusion reactions and infection. 
Screening and vaccination before starting bDMARDs is important and poorly adhered to 
Keywords  





Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have dramatically improved 
outcome in patients with severe immune-mediated diseases (IMD). They are indicated in 
autoimmune diseases that have shown a poor response to conventional therapy, and 
recommendations for their use have been published by international and national bodies 
representing various subspecialties (1,2).    
 
All bDMARDs increases the risk of serious infection (2–5). In sub-Saharan Africa, there is a 
heavy background burden of infectious diseases, including tuberculosis (TB), human 
immune virus (HIV), and hepatitis B (HBV) and hepatitis C virus (HCV) and these need careful 
monitoring in patients using any bDMARD treatment (3,6). The concern of serious infection, 
together with the high cost of these therapies, hampers the widespread use of bDMARDs in 
resource-constrained settings and evaluates efficacy and safety practices associated with 
their use vital.  In the South African (SA) state- sector, resource constraints mean that very 
few state-sector patients are offered bDMARDs(3). Each clinical division needs to motivate 
for a bDMARD to the pharmacy therapeutics committee on a named patient basis. 
Alternatively, patient self-funding, medical insurance schemes, or clinical trials are ways of 
accessing these therapies. In SA, there are considerable variations in access to bDMARDs 
between hospitals and provinces. 
 
We undertook this study to assess the number of patients, indications for, and specific 
bDMARD therapies used, in addition to monitoring efficacy, adverse events and screening 
practices. We believe an understanding of these metrics will improve our current use and 
future planning of therapies for refractory patients. 
 
Patients and Methods  
This retrospective study includes all patients treated with bDMARDs for IMD at a tertiary 
referral hospital. We included any patient given bDMARDs (minimum one dose) between 
January 2013 and December 2019 and excluded patients treated for haematological 
malignancy.  To ensure all patients using bDMARDs were included, lists were obtained from 
each clinical department, and the hospital pharmacy.  
Folders were reviewed, and demographic and clinical details including the IMD details and 
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disease duration, use of immunosuppressant before bDMARDs, and screening procedures 
were documented. Disease activity, measured by accepted disease-specific tools, were 
documented at baseline, 6-, 12- and 24- months, and at the last available encounter, 
together with adverse events and reason/s for discontinuation of treatment. Besides, 
patient adherence was assessed by reviewing the pharmacy records of prescriptions filled.  
 .  
The Student’s t-test was applied to compare continuous variables between independent 
groups, except where there was non-normal distribution in which case the Wilcoxon rank-
sum (Mann Whitney) test was used. A p-value of 0.05 was considered significant. Statistical 
analyses were done using Statistica 13.5.17software. This study was approved by the 
University of Cape Town Human Research Ethics Committee. 
 
Results 
We reviewed 151 folders, with 182 bDMARDs prescribed (29 patients used more than 1 
bDMARD), of which 100 were females and 51 males; 91 were adults and 60 pediatric 
patients (Table 1). Eleven folders were excluded from the study because they were lost, 
destroyed or empty. The adult patients were Crohn`s disease (CD) (26), rheumatoid arthritis 
(RA) (13), spondyloarthritis (SpA) (10), ophthalmology (10), psoriasis (PSO) (9), systemic 
lupus erythematosus (SLE) (5), ulcerative colitis (UC) (5), idiopathic inflammatory myopathy 
(IIM) (5), neurology (4), and other diagnoses (4). The pediatric patients were juvenile 
idiopathic arthritis (JIA) (26), ophthalmology (15), SLE (12), vasculitis (3) and other diagnoses 
(4). The vast majority of bDMARDs were state-funded, with 7 patients paying for their 
bDMARDs personally or through private medical insurance, and 1 patient enrolled in a 
clinical trial. Disease duration before starting bDMARD therapy was long (mean (SD) 7.08 
(7.21)), and the majority of patients had used numerous immunosuppression before 
bDMARDs, reflecting the poor access to these expensive therapies. 
 
Disease activity and response to treatment 
As expected, the vast majority of patients showed significant improvements in disease 
activity on bDMARD therapy (Table 2 and 3). Amongst RA and SpA patients, 66.6% achieved 
low disease activity. Improvements were seen in 88.8% of PSO patients, 80.0% of 
Inflammatory bowel disease (IBD) patients, 84.6% of JIA patients and all ophthalmology 
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patients. There were a few patients who showed no improvement – the CD with fissure on 
TNFi, and the adult-onset still disease (AOSD), polymyositis (PM), juvenile dermatomyositis 
(JDM) and 2 neurology patients treated with RTX. Most adult and paediatric SLE patients 
improved except for two patients with nephritis.  
 
Screening practices 
We reviewed the screening and vaccination practices prior to bDMARD initiation (Table 4). 
In terms of TB, 12 (7.9%) patients reported previous TB, chest radiographs (CXR) were 
abnormal in 5 (3.3 %) patients, normal in 140 (92.7 %) patients and not performed in 6 
(4.0%) patients. Screening for latent TB infection (LTBI) with a tuberculin skin test (TST) was 
positive in 10 (6.6%) patients, negative in 45 (29.8 %), and not done in 96 (63.6%). Of the 
patients treated with TNFi, only 37/88 (42%) had a TST performed. Of these 12/37 (32.4%) 
were from rheumatology, 2/37 (5.4%) in dermatology, 12/37 (32.4%), in gastroenterology, 
7/37 (18.9%) in JIA, and 4/37 (10.8%) in pediatric ophthalmology.  However, the decision 
was made in some subspecialties to prescribe long-term isoniazid (INH) prophylaxis to all 
patient on TNFi, thus the TST was not always performed as the results were felt to be 
irrelevant. Long-term INH prophylaxis was given to 71/151 (47%) bDMARD patients, and to 
44/88 (57.9%) of the patients prescribed TNFi therapy. Of these, 21/44 (47.7%) from 
rheumatology, 13/44 (29.5) ophthalmology, 11/44 (25%) in gastroenterology, and 2/44 
(4.5%) in dermatology). Short term INH prophylaxis for 6-months was given to 10/151 
(6.6%) bDMARDs patients and to 7/88 (8%) of patients prescribed TNFi therapy.  
 
Screening for HBV surface antigen (HBsAg) was performed in 93 (61.6%) patients, and by 
division, 33.3% in rheumatology, 29% in gastroenterology, 11.8% in pediatric rheumatology, 
and under 10% in all other Departments The vast majority of patients (72.2%) had no testing 
for HBV core antibody (HBcab), and 36 (33 %) of these patients were treated with RTX. 
 
HCV screening was performed in 81 (53.6%) patients. Of these,37% in rheumatology, 23.5% 
in gastroenterology, 11.1% in pediatric rheumatology and under 10% in other Departments.   
 
HIV testing was performed in 88 patients (58.3%). Three patients were HIV positive and 
virally suppressed before starting bDMARDs.  
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In terms of vaccination, few patients received influenza or pneumococcal vaccine  
(17.2%)and (15.8%) respectively. 
 
Adverse events and discontinuation 
Thirty adverse reactions were recorded, and mild skin adverse reactions were the 
commonest problem, followed by infection (table 5). Two patients had mild infection lead to 
temporary stopping the bDMARDs, and eight patients had severe infections, necessitating 
discontinuation of bDMARD in five. These included two patients with TB, the first patient 
with SpA completed 3 years of etanercept (ETN) with chronic INH prophylaxis and presented 
with constitutional symptoms and a chest X-ray showing hilar lymphadenopathy. Sputum 
gene expert and culture were negative, mediastinal lymph node biopsy showed 
granulomatous inflammation, but Zeil-Nelsen stain was negative. The ETN was discontinued 
and the patient improved with 6 months of empiric TB therapy. The second patient with RA 
treated with adalimumab with a negative TST and no INH prophylaxis developed 
disseminated TB during the first 6 months of bDMARD therapy. Pneumocystis Jiroveci 
pneumonia (PJP) was diagnosed in an HIV negative RA patient after nearly 4 years of ETN 
treatment.  Varicella was diagnosed in a JIA patient treated to remission with ETN for 3 
years. 
Eighteen patients (11.9 %) discontinued bDMARDs, with infection 5/18 (27.8%), poor 
response 3/18 (16.7%), or poor adherence 4/18 (27.8%) being the common reasons for 
discontinuation. One JIA patient stopped treatment after 9 months of Tocilizumab due to 
suspected macrophage activating syndrome. One patient became HIV positive during 
bDMARD treatment,   and the bDMARD was stopped given his inactive disease. 
 
HIV positive patients 
Of the three HIV positive patients, two had polymyositis (PM), and received RTX after failing 
numerous immunosuppressive therapies. Both had a mild to moderate clinical and 
laboratory response to RTX.  The third patient with JIA achieved remission with ETN. None 
of these patients experienced adverse effects and had undetectable viral loads and normal 





There were 29/151 (19.2%) patients switching bDMARDs, and two of them switched to 
more than one bDMARD (tables 6 and 7). The most common reasons for switching 




Poor adherence to bDMARDs therapy was observed in 17/151 (9.3 %), and also, four 
patients were lost to clinic follow-up. Despite our attempts to trace these patients, no 
details are available. These patients may have relocated or may have died at home. 
 
Discussion 
We have described the patients using bDMARD at a tertiary referral hospital and show that 
the commonest class of bDMARDs prescribed is TNFi (61.5%), followed by rituximab (RTX) 
(30.2%), with the most common indications including inflammatory arthritis, IBD, PSO and 
scleritis.  Most bDMARDs were state-funded. The vast majority of patients had an excellent 
response to bDMARDs, which is encouraging, despite the long disease duration and 
numerous immunosuppressants used before starting bDMARDs.  
 
Validated disease assessment scores were documented in the folders of most patients. A 
serum C-reactive protein (CRP) was seldom performed in bDMARD patients, and this may be 
an area for improvement, given that CRP is a useful measure of inflammation, and may also 
be a marker of TB or other chronic infection(7). The assessment of functional status was 
very poor, with no regular assessment in either adult or pediatric rheumatology patients. 
Assessing functional status is vital to assess how symptoms affect patients, and to measure 
whether therapy is improving the quality of life. 
 
Screening for latent TB is recommended by international and local recommendations before 
starting bDMARDs (2,5,8–10). Adherence to screening was worryingly poor, given the high 
prevalence of TB in SA. Although the majority of patients had a CXR, almost a third of 
patients using bDMARDs had no documented TST. A limited supply of purified protein 
derivative in the last two years in SA may explain the lack of TST testing.  The expense and 
lack of availability of interferon-gamma release assay in the state-sector limited its use. In a 
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multicentre retrospective study of Crohn's disease patients using TNFi in Dutch, the 
adherence to screening for LTBI was 76%(11). INH prophylaxis was only prescribed for 58.0% 
of patients on TNFi, 52.5%of adults, and 69.0% of pediatric patients, despite the high 
incidence of TB in SA. Besides, we showed very poor adherence to HBV and HCV testing. 
Studies from elsewhere have shown that adherence to these recommendations is poor 
(12,13).  
Only 41.7% of patients using bDMARDs in this study had an HIV result available, although SA 
has one of the highest prevalence of HIV infection in the world. There is currently little 
literature available regarding the safety of bDMARDs in HIV positive patients (14). Vigilance 
in knowing the patient’s HIV status may guide clinicians’ decisions of bDMARD and 
prophylactic medications will also contribute to the scientific knowledge available. 
 
All bDMARDs therapies modulate the immune response as part of their mechanisms of 
action, and therefore they may increase the risk of developing infections, particularly in 
older patients or in patients with concomitant corticosteroids. Some of these infections may 
be preventable by immunization (15). Before commencing bDMARDs therapy, immunization 
for influenza, pneumococcal, human papillomavirus and HBV are recommended (3,16–18). 
In the current study, immunization for influenza and pneumococcus was vaccine 
suboptimal. 
 
Almost 10% of patients were poorly adherent to their bDMARDs, particularly rheumatology, 
IBD, and pediatric patients. Reason for poor adherence included a poor understanding of 
bDMARDs, poor socioeconomic status, adverse effect, and cost.  In a recent study of 
patients treating with bDMARDs in five different European countries, 56.3% of patients 
missed a dose in the last 6 months. The reasons for noncompliance were feeling better and 
didn’t need it, thinking the therapy was not helping, or sickness, surgery or infection (19). 
Adherence to bDMARDs therapy in a patient with PSO is low with a high discontinuation 
rate (20). A prospective study of TNFi in SA showed a third of the patients discontinue TNFi 
within one year of treatment(21).  We recommend a focus on patients’ socio-economic 




Limitations of this study include the retrospective design, with missing folders, and missing 
details including function status, and CRP. The other limitation was the lack of specific 
measurement of activity in some diseases.  
 
In conclusion, bDMARDs in our hospital were effective, and generally safe, with the most 
common adverse effects being infusion reaction, and infection, with TB occurring in two 
patients. We note poor adherence to TB and viral hepatitis screening and vaccination before 
commencing bDMARDs. Also, adherence to bDMARDs was suboptimal. We recommend the 
preparation of standard operating procedures for all patients using bDMARDs across all 
disciplines, including details of screening tests before starting bDMARDs, assessment of 
functional status in patients, and intense patient education and counselling. Further studies 
are planned to assess the success of these interventions. 
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Table 1:  Details of 151 patients prescribed bDMARDs 














TNFI    RTX TCZ OTHER* 
RHEUMATOLOGY 
 N=38  
RA 13 34.6 (12.6) 9 (10.1) 4 4 9 0 0 
SpA 10 33 (7.1) 8.7 (8) 3 10 0 0 0 
SLE 5 20 (4.2) 5.6 (5.6) 5 0 5 0 0 
AOSD 1 26    5  4 0 1 0 0 
IgG4-RD 1 35  3  1 0 1 0 0 
IIM 5 38.8 (8.5) 8.6  6 0 5 0 0 
PsA 1 33   4 1 0 0 0 
ANCA-Vasculitis 1 22  7  3 0 1 0 0 
DERMATOLOGY N=9 PSO 9 38.9 (15.7) 19.3 (9.6) 4 9 0 0 0 
GASTROENTEROLOGY  
N=31 
CD 25 24 (10.9) 7.6 (5.8) 5 25 0 1 0 
UC 5 23.6 (18.3) 9.8 (5.3) 4 5 0 0 0 
Skin-CD 1 26  19 2 1 0 0 0 
NEUROLOGY 
 N=4 
M gravis 1 13  31  3 0 1 0 0 
PM 1 32  10  2 0 1 0 0 
NMO 1 34  3  2 0 1 0 0 
MS 1 24  .2  0 0 1 0 0 
OPHTHALMOLOGY  Uveitis 4 21.5 (24.1) 5.4 (4.6) 4 4 0 0 0 
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N=10 Scleritis 5 36.8 (13.4) 4.8 (3.7) 6 1 4 0 0 




JIA 26 7.6 (4.3) 4.6 (5.2) 6 21 3 8 2 
SLE 12 9.8 (3.4) 9.8 (3.7) 6 0 12 0 0 
Vasculitis 3 10.6 (1.2) 4 (1.7) 5 0 3 0 0 
Sweet syndrome 1 1  2  1 0 0 0 1 
CRMO 1 8  2  2 1 0 0 0 
Autoinflammatory 
syndrome 
1 10  7.8  3 1 0 0 0 




Uveitis 14 6.2 (2.7) 2.8 (1.8) 4 14 0 0 0 
Optic neuritis 1 9  7  2 0 1 0 0 
*other – Abatacept, Anakinra 
** previous immunosuppressants: Methotrexate, Sulphasalazine, Chloroquine, Leflunomide, Cyclophosphamide, Azathioprine, Mycophenolate 
Mofetil, Cyclosporin, and Tacrolimus. 
 Abbreviations:    i/s: immunosuppressant; AOSD: Adult-Onset Still Diseases; CD: Crohn`s disease; CRMO: Chronic Recurrent Multifocal 
Osteomyelitis;  IgG4-RD: Immunoglobulin 4 Related Diseases; IIM: Idiopathic inflammatory myopathy; JDM: Juvenile Dermatomyositis;  JIA: 
Juvenile Idiopathic Arthritis; M Gravis: Myasthenia Gravis; MS: Multiple Sclerosis;  PM: Polymyositis; NMO:  Neuromyelitis Optica; PsA: 
Psoriatic Arthritis; PSO: Psoriasis; RA: Rheumatoid Arthritis; SpA: Spondyloarthritis;  Skin CD: Skin Crohn`s disease; SD: Standard Deviation;  




 Table 2:  Outcomes in adults treated with bDMARDs 













   CDAI  
 
60.8 (34.4)  17.0 (14.2)  19.7 (10) 
 







4.5 (2.6)  2.8 (0.2) 
 
<0.0001 2.8 (0) 
 
6 (66.6%) 




8.4 (1.5)  5.7 (2.0)  0.03  - 
PSO 
n=9 
 BSA 29.1 (12.5)  9.6 (13.2) 
 















IgG4_RD C/F dyspnea improved improved  NI 1 (100%) 
GPA C/F Subglottic 
stenosis 
stable stable  inactive 1 (100%) 








PM n=4 CK U/L 1955 (1365)  2352 (1695)  1520 (1907)  0.72 (1227, 0) 
 
0  






 2.8 (0) 
 









AIHA n=3 Hb g/dl 6.8 (2.9)  11.6 (3) 
 







































11.3/ 1.53/ 198  
 







8 (0) 2 (0) 2 (0)  NI 1 (100%) 
 LN n=2 UPCR 0.7 (.4) 0.7 (.5) 0.8 (0) 0.9 NI 0 
 NPSLE 
n=1 













1 ( 0) 
 
NI  NI Improved  





Valid   
NMO C/F Weak  Weak NI  NI 0  














































CD n=26 C/F D=8,  
PAD(F)=10,  
CDF=11, 



























*p-value comparing baseline and 12-month  
**Definitions of satisfactory response were disease-specific as follows: Satisfactory response in SpA: BASDAI score < 4; Antisynthetase 
syndrome: improvement in FVC; AOSD: CDAI ≤10;  CD and UC: improvement in clinical features (diarrhoea, bloody stool, abdominal cramps, 
arthralgia, nausea and vomiting, fistula, perianal discharge, perianal abcess, wound dehiscence);  GPA: improvement in subglottic stenosis; 
IgG4-RD: improvement in wheeze and breathing difficulty;  IIM: decreased CK and clinically improved in CSM; M Gravis: improvement in MGCS 
and C/F; MS: improvement in EDSS score and C/F;  NMO: improved weakness; PM: improvement in CK and MMT; PSO: BSA%≤10%; PsA: CDAI 
≤10;  RA: remission or low disease activity (CDAI ≤10); SLE arthritis: active joints count ≤2; SLE AIHA: return Hb to normal; SLE Pancytopenia: 
improvement in Hb, Plt and WBCs; SLE Pulmonary Vasculitis: improved in cough and air entry;  SLE Pneumonitis, SLS:  improvement in FVC; 
SLE thrombocytopenia: increased platelet > 100 X 109/L; Uveitis and Optic neuritis: improvement of VA; Ulcerative Keratitis: improvement in 
vision and inflammation). 
Abbreviations: AOSD: Adult Onset Still Diseases; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFAI: Bath Ankylosing 
Spondylitis Functional Index; BIS: Blood in stool; BSA%: Body Surface Area %; CD: Crohn`s disease; CDAI: Clinical Disease Activity Index; CDF: 
CD flare; C/F: clinical features; CWC: Clinically well controlled; D: Diarrhoea; Hb: Haemoglobin; CK: Creatine Kinase; CRMO: Chronic Recurrent 
Multifocal Osteomyelitis; EDSS: Expanded Disability Status Scale; FVC: Forced Vital Capacity: IgG4-RD: Immunoglobulin 4 Related Diseases; IIM: 
Idiopathic inflammatory myopathy; ILD: Interstitial Lung Disease; JDM: Juvenile Dermatomyositis; JIA: Juvenile Idiopathic Arthritis; LN: Lupus 
Nephritis; M Gravis: Myasthenia Gravis; MGCS: Myasthenia Gravis Composite Score; MMT: Manual Muscle testing; MS: Multiple Sclerosis; NI: 
Non Indicated; NMO: Neuromyelitis Optica; NPSLE: Neuro-Psychiatric SLE; PAD(F): Perianal discharge and fistula:  Plt: platelet; PsA: Psoriatic 
Arthritis; PM: Polymyositis;  PSO: Psoraisis; RA: Rheumatoid Arthritis; SpA: Spondylarthroses; SD: Standard Deviation; SLE: Systemic Lupus 
Erythematosus; SLS: Shrinkage Lung Syndrome;  TCZ: Tocilizumab; TNFi: Tumour Necrosis Factor Inhibitor; UC: Ulcerative Colitis; UCF: 






   Table 3: Outcomes in paediatric patients treated with bDMARDs  
Disease Outcom










No (%) with 
satisfactory 
response* 


























 86  
 
  1 (100%) 
















otitis media  
 Improved  1 (100%) 








 CRMO  
n=1 
C/F Flare > 3 lesions ongoing 
active 
lesions 
   Slight improvement 











*Satisfactory response in JIA: remission or low disease activity (cJADAS-10 less or = 1.5 in Oligo JIA, less or =.2.5 in Poly JIA);  JDM: decreased 
CK and clinically improved in CSM: MPA-ILD: Improvement in FVC: MPA-CN: improvement in Creatinine; PAN-Panniculitis: resolve of skin 
lesions; AIIS: resolved of the rash and Otitis media; Sweet Syndrome: resolved of skin lesions; CRMO: number of infected areas. 
**p-value comparing baseline and 12-month  
 
Abbreviations: AIHA: Auto-immune Haemolytic anaemia; AIIS: Autoimmune Inflammatory Syndrome; CDAI: Clinical Disease Activity Index; 
C/F: Clinical features; CK: Creatine Kinase; cJADAS-10: clinical JIA Disease Activity Index 10 joints count; CRMO: Chronic Recurrent Multifocal 
Osteomyelitis; JDM: Juvenile Dermatomyositis; JIA: Juvenile Idiopathic Arthritis; LN: Lupus Nephritis; MPA-CN: Microscopic Polyangiitis 
associated Crescentic Nephritis; MPA-ILD: Microscopic Polyangiitis associated Interstitial Lung Disease; NPSLE: Neuro-Psychiatric Systemic 
Lupus erythematosus; PAN: Polyarteritis Nodosa; SD: Standard Deviation. 
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Table 4: Screening prior to prescribing bDMARDs   
















Abbreviations:  bDMARD: biologic disease-modifying anti-rheumatic drugs; CXR: Chest X-Ray; HBsAg: HBV Surface Antigen; HBcab: HBV core 
antibody; HIV: Human Immune Virus; INH: Isoniazid; pts: patients; TB: TB: TST: Tuberculin Skin Test; TNFi: Tumour Necrosis Factor-alpha 
inhibitor.                    
 Screening procedure Positive or abnormal Negative or normal Not performed (n, %) 
TB History of TB 12/151 (7.9) 139/151 (92.1%) 0 
 CXR 5/151 (3.3%) 140/151 (92.7%) 6 /151(4%) 
 TST 10/151 (6.6%) 45/151 (29.8%) 96/151 (63.6%) 
 TST (Patients on TNFi) 9/88 (10%) 28/88 (32%) 51/88 (58%) 
 INH prophylaxis all bDMARDs 81 (53.6%)  70/151 (46.4%) 










Hepatitis B HBsAg 2/151 (1.3%) 91/151(60.3%) 58/151 (38.41 %) 
 Patients on RTX 0 33/51 (64.7) 18/51 (35.3%) 
 HBcab 2 (1.3%) 40 (26.5%) 109 (72.2%) 
 Patients on RTX 1/51 (2%) 14/51 (27.4%) 36 (70.6%) 
Hepatitis C  0 81(53.6%) 70 (46.4%) 
HIV   3 (2%) 85(56.3%) 63 (41.7%) 
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Table 5: Side effects, discontinuation and adherence to bDMARDs                                       
Problem Details Number (%) 
Adverse reaction 
n=30 (16.5%) 
Mild reaction (rash and itching) 14 (7.7%) 
Severe allergic reaction 3 (1.6%) 
Infection – all  10 (5.5%) 
- TB 2 (1.1%) 
- PCP 1 (.5%) 
- Septicemia 3 (1.6%) 
- Varicella  2 (1.1%) 
- Mild infection 2 (1.1%) 
Other - ILD, elevated liver enzymes 3 (1.6%) 
Temporarily stopped 
n=8 (5.3%) 
Infection 2 (1.1%) 
Other Adverse Events 2 (1.1%) 
Poor adherence 1 (.5%) 
Financial or social 1 (.5%) 
Clinical Trial stopped 2 (1.1%) 
bDMARDs discontinued  
n=18 (11.9%) 
Poor response 4 (2.2%) 
Remission 1 (.5%) 
Infection 5 (2.7%) 
HIV positive 1 (.5%) 
Other Adverse Events * 2 (1.1%) 
Lost to follow up or defaulted treatment 4 (2.2%) 
Medical aid stopped  1 (.5%) 
Poor adherence 
n=18 (9.9%) 
Failed to collect medication or attend the 
clinic 
17 (9.3%)  
Unable to afford bDMARD 1 (.5%) 
 
 
  * 1 elevated liver enzymes, I worsening ILD. 1 reaction to rituximab 
Abbreviations:  bDMARDs: biologic Disease-Modifying Anti-Rheumatic Drugs, ILD: 
Interstitial Lung Disease, PCP: Pneumocystis Carinii Pneumonia.                             
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Table 6 (supplementary): Table 6 Patients using more than 1 bDMARD (total 27 bDMARDs) 
Diagnosis bDMARD 1 n= 27 Reason for 
change 
n (%) bDMARD 2 n= 27 Respond n (%) 
JIA n=1, PSO n=1,  
AS n=1,  




Poor response 10 (38.5 %)  TNFi  n=6 
Rituximab  n=2 
Tocilizumab  n=1 
Abatacept  n=1 
7/10 (70%) 




3 (11.1%) Tocilizumab  n=2 
Rituximab  n=1 
3/3 (100%) 
CD n=1,    JIA  n=1, PSO n= 1, 
UC  n=1,  SLE n=1  
TNFi n=3 





5 (18.5%) TNFi  n=3 
Anakinra  n=1 
RTX  n=1 
5/5 (100%) 
SLE  n=1 
PSO  n=1 AIIS  n=1 
TNFi  n=1 
Tofacitinib n=1 
Not documented 3 (12.5%) TNFi  n=3 3/3 (100%) 
PSO  n=1 Infliximab  Medical aid 
stopped 
n=1 Etanercept Partially 
improved  
PSO  n=1 Adalimumab  Clinical Trial 
stopped 
n=1 Infliximab 1 (100%) 
PSO  n=1 Etanercept  Cost  n=1 Etanercept 1 (100%) 
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Abbreviations: AIIS: Autoimmune Inflammatory Syndrome; AS: Ankylosing spondylitis; CD: Crohn`s disease; JIA: Juvenile Idiopathic Arthritis; 
IIM: idiopathic immune-mediated myopathy; PSO: Psoriasis; SLE: systemic lupus erythematosus; US: ulcerative colitis.  
CD  n=1 Infliximab  Patient 
preference 
n=1 Adalimumab  1 (100%) 
CD  n=1 Infliximab  not approved by 
pharmacy 
n=1 Adalimumab  0 
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 Table 7 (supplementary): Patients using more than 2 bDMARD (total 5 bDMARDs) 
 
 



































2 Tocilizumab  2 (100%) 
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